Medicare Covers Signatera MRD Test in Liver Cancer, Opening New Surveillance Market
NTRA has more than doubled off its 52-week low of $181.
Summary
CMS's MolDX program will now pay for serial Signatera testing in hepatocellular carcinoma surveillance for early-stage patients with no evidence of disease after surgery. That is a new reimbursed indication for the company's fastest-growing franchise, and HCC is the most common primary liver cancer, with more than 42,000 new U.S. liver cancer cases expected in 2026. The decision rests on a 125-patient real-world study in JCO Precision Oncology where Signatera showed 83% sensitivity versus 42% for AFP at 100% specificity, with lead time up to 16.5 months ahead of imaging (median 7.9 months) versus 2.2 months for AFP. It extends a run of Signatera wins — Japan PMDA approval in September, the AFT-70 Phase III trial launch in October, and FDA Breakthrough designation for the MCED assay — and follows Q2 revenue of $752.8M, up 38%, with oncology volumes up 57%. Coverage removes the payer hurdle for a surveillance use case that recurs over years, so the revenue effect builds through 2027 rather than landing in one quarter.
At the time of this announcement, NTRA was trading at $380.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $54.6B. The 52-week trading range was $181.00 to $437.41. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.